Company

ProMIS Neurosciences, Inc.

ProMIS Neurosciences develops antibody therapies targeting misfolded proteins in neurodegenerative diseases.

About

Founded in 2015, ProMIS Neurosciences develops antibody therapeutics targeting toxic misfolded proteins associated with Alzheimer’s disease, ALS and multiple system atrophy. Its work includes computer modeling and the PMN310 monoclonal antibody candidate for Alzheimer’s disease. The company is based in Toronto and trades on NASDAQ as PMN. In August 2023, it raised USD 20.4 million through a PIPE investment led by Affinity Asset Advisors, Ally Bridge Group and Sphera Healthcare Us Inc.

2Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in